A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060

DermaGen AB1 site in 1 country41 target enrollmentMarch 2008

ConditionsAtopic Dermatitis

InterventionsDPK-060 1% ointment Placebo for DPK-060 ointment

DrugsDPK-060 1% ointment Placebo for DPK-060 ointment

Overview

Phase: Phase 1
Intervention: DPK-060 1% ointment
Conditions: Atopic Dermatitis
Sponsor: DermaGen AB
Enrollment: 41
Locations: 1
Primary Endpoint: Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study was to evaluate microbial density in eczematous lesions during two weeks of twice daily therapy with the investigational product, DPK-060 1% ointment, compared with placebo in patients with atopic dermatitis. This randomized, double-blind, placebo-controlled part of the study was preceded with an open-label investigation in a small group of patients (n=5) treated with two applications of DPK-060 1% ointment per day for four days to assess safety, local tolerability and systemic absorption of DPK-060.

The secondary objectives were to evaluate severity of eczema and pruritus, to assess the tolerability and safety of the treatment and to assess the degree of systemic absorption of DPK-060 in blood on Day 7 and Day 21 in a sub-set of 10 patients.

Registry

clinicaltrials.gov

Start Date

March 2008

End Date

April 2009

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

DermaGen AB

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A clinical diagnosis of atopic dermatitis
•Treatable eczematous lesions of a total area of at least 25 cm2 (100 cm2 for the initial five patients)
•Female patients of childbearing potential had to be using an appropriate method of contraception.
•Female patients of childbearing potential were not eligible before PK data from the first 10 patients had been evaluated and the Medical Products Agency (Swedish regulatory agency) had given approval to include women of childbearing potential.

Exclusion Criteria

•Significant clinical illness, within the two weeks prior to first dose, which could affect the outcome of the study
•Previous local or systemic antimicrobial therapy within the last four weeks prior to the first application of the investigational product (DPK-060 1% or placebo ointment)
•Existence of any surgical or medical condition which, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug
•Patients who had had systemic treatment for atopic dermatitis or other topical or transdermal treatments (such as nicotine, hormone replacement therapies)on the site of eczema within 14 days prior to first application of DPK-060 1% or placebo ointment and/or topical treatment with tar, any corticosteroid,topical immunomodulators or oral treatment with any corticosteroids within 14 days prior to first application and/or oral antihistamines within 14 days of the first dose.
•A need for any other medication during the period 0 to 7 days before entry to the study, (excluding the oral contraceptive pill for females) except those deemed by the principal investigator / clinical investigator not to interfere with the outcome of the study
•Diagnosis of other skin diseases, which in the opinion of the investigator, were likely to adversely affect the outcome of the study
•History or evidence of significant cardiac, renal, hepatic or endocrine disease
•Significant hypersensitivity or allergy, as judged by the investigator
•Immunocompromised patients
•Lice or scabies

Arms & Interventions

DPK-060 1% ointment

Intervention: DPK-060 1% ointment

Placebo for DPK-060 ointment

Intervention: Placebo for DPK-060 ointment

Outcomes

Primary Outcomes

Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Full Analysis Set

Time Frame: Baseline and Day 14

The total microbial colony forming units count is the number of CFU/cm2 for total microbial count in eczematous lesions.

Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 14 Per Protocol Analysis Set

Time Frame: Baseline and Day 14

The total microbial colony forming units count is the number of CFU/cm2 for total microbial count in eczematous lesions.

Secondary Outcomes

Percent Change From Baseline in KNS CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 7 and 21 Per Protocol Analysis Set(Baseline, Day 7 and 21)
Percent Change From Baseline in S.Aureus CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Percent Change From Baseline in Total Microbial Colony Forming Units (CFU) Count at Day 7 and 21 Full Analysis Set(Baseline, Day 7 and 21)
Percent Change From Baseline in KNS CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Percent Change From Baseline in Gram-positive Bacteria CFU Count at Day 7, 14 and 21 Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Percent Change From Baseline in Gram-positive Bacteria CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Change in Total Treated Eczema Area Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Change in Total Treated Eczema Area Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Erythema Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
Excoriations Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
Infiltration Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
Percent Change From Baseline in S.Aureus CFU Count at Day 7, 14 and 21 Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Change in Area of Microbial Counting Site Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Erythema Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
Lichenification Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
Lichenification Eczema Area and Severity Index (EASI) Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
Investigator's Global Assessment of Eczema Change Full Analysis Set(Day 7, Day 14 and Day 21)
Investigator's Global Assessment of Eczema Change Per Protocol Analysis Set(Day 7, Day 14 and Day 21)
Change in Area of Microbial Counting Site Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Excoriations Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
Infiltration Eczema Area and Severity Index (EASI) Full Analysis Set(Day 7, Day 14 and Day 21)
Change From Baseline in Visual Analog Scale of Itching (VASI) Full Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Change From Baseline in Visual Analog Scale of Itching (VASI) Per Protocol Analysis Set(Baseline, Day 7, Day 14 and Day 21)
Patient's Global Assessment of Eczema Change Full Analysis Set(Day 7, Day 14 and Day 21)
Patient's Global Assessment of Eczema Change Per Protocol Analysis Set(Day 7, Day 14 and Day 21)